Condition category
Nutritional, Metabolic, Endocrine
Date applied
02/05/2013
Date assigned
23/05/2013
Last edited
23/05/2013
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Iron deficiency or anemia is the most common nutritional deficiency in the world. Infants and young children are at the highest risk of anemia because they have higher iron requirements. Iron syrup or drops are good in preventing or treating anemia but most children do not like them because of bad taste, therefore compliance is poor. There is an alternative method to treat anemia. Iron and micronutrients in powder (MNP) can be sprinkled and mixed with a portion of the baby food. They do not change the color or the taste of food. They are well accepted. Research shows that MNPs are good in reducing anemia. However, there is no agreement about how much should be used and for how long. This study aims to investigate the best usage of MNPs, with respect to the number of sachets, duration and form (daily or intermittent).

Who can participate?
Children 6-11 months old, living in the city of Cajamarca, Peru, born at term, with birth weight > 2.5 kg, without severe illness, severe anemia and severe malnutrition can participate.

What does the study involve?
Children are randomly allocated to one of four groups using a computer program. They will receive supplementation daily or weekly for 6 months or one year. All children will be followed for 12 months . There are blood tests at the beginning, during and after the study. All information collected are kept confidential.

What are the possible benefits and risks of participating?
Benefits include free examination by the pediatrician, supplements, lab analyses and health care. The information will help decide the best supplementation for small children. The dose of supplements is based on international recommendations of daily intake of nutrients. There is a low risk that blood drawn may cause a hematoma.

Where is the study run from?
The study is conducted in Cajamarca, Peru.

When is the study starting and how long is it expected to run for?
September 2011 to June 2013.

Who is funding the study?
Micronutrient Initiative, Canada
Lab analyses are supported by Sight and Life, Switzerland

Who is the main contact?
Dr. David Loza
lozadavid@yahoo.es

Trial website

Contact information

Type

Scientific

Primary contact

Dr Nelly Zavaleta

ORCID ID

Contact details

Instituto de Investigación Nutricional
Av. La Molina 1885 - La Molina
Lima
Lima 12
Peru
511-3496023
nzavalet@iin.sld.pe

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

IIN-282

Study information

Scientific title

Defining criteria to establish the optimum scheme of supplementation with micronutrient powder in children: unblinded randomized controlled trial

Acronym

Study hypothesis

To investigate what is the optimal scheme of supplementation with MNP, regarding the number of sachets, duration and form of supplementation (daily or intermittent).

Ethics approval

1. Instituto de Investigacion Nutricional (IIN) Review Board (IRB) approved on the 14-03-2011: Reference 308-2011/CEI-IIN
2. Peruvian National Institute of Health authorized on the 10-06-2011. Reference 506-2011-DG-OGITT-OPE/INS

Study design

Unblinded randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Prevention

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Anemia

Intervention

There are 4 groups of supplementation:
1. Children from 6 to 11 months of age, who consume the micronutrient powder supplement intermittently for 6 months (90 doses), will have a significant decrease in the prevalence of anemia and micronutrient deficiency (control group)
2. Children 6 to 11 months of age, who consume the micronutrient supplement powder intermittently for 12 months (180 doses), will have a greater decrease in the prevalence of anemia and micronutrient deficiency compared with the control group. (Group I)
3. Children 6 to 11 months of age, who consume the micronutrient supplement powder daily for 6 months (180 doses), will have a greater decrease in the prevalence of anemia and micronutrient deficiency compared with the control group. (Group II)
4. Children 6 to 11 months of age, who consume the micronutrient supplement in powder on a daily basis for 12 months (360 doses), will have a greater decrease in the prevalence of micronutrient deficiency anemia and the control group and groups I and II. (Group III).
The participation in a group is randomized, using a computer program

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

Anemia prevalence. All children are followed for 12 months, at entry and every month children are examined by a pediatrician at the outpatient clinic, every 2 weeks a field worker visits the child´s home to record compliance and morbidity, at entry and at the end of supplementation a venous blood sample of 5 ml is taken to measure hemoglobin, and micronutrients. In 2 more times we will take a drop of blood from the finger to measure hemoglobin.

Secondary outcome measures

1. Growth (weight and length)
2. diarrhea prevalence
3. micronutrient status (ferritin, transferrin receptors)
4. vitamin A
5. vitamin B12
6. zinc and folate status
7. inflamatory markers (CRP, AGP)

Overall trial start date

01/09/2011

Overall trial end date

01/06/2013

Reason abandoned

Eligibility

Participant inclusion criteria

1. Children between 6 months and 11 months and 29 days old
2. Residents in the city of Cajamarca and communities near the Health Center Baños del Inca
3. Born at term
4. Birth weight ≥ 2500 g
5. Healthy
6. Hemoglobin> 8 g/dL (corrected for altitude)
7. Weight / length> -2 SD
8. Parents agree and sign the informed consent form

Participant type

Patient

Age group

Child

Gender

Both

Target number of participants

400

Participant exclusion criteria

1. Children younger than 6 months, or more than 12 months
2. Non-residents in Cajamarca (intervention site)
3. Children with initial hemoglobin below 8 g/dL (corrected for altitude) will be evaluated by the doctor to discard additional pathology and will be treated according to Ministry of Health standards
4. Weight/length below - 2 DE
5. Chronic, congenital or severe diseases
6. Parents do not sign the informed consent form

Recruitment start date

01/09/2011

Recruitment end date

01/06/2013

Locations

Countries of recruitment

Peru

Trial participating centre

Instituto de Investigación Nutricional
Lima
Lima 12
Peru

Sponsor information

Organisation

Micronutrient Initiative (Canada)

Sponsor details

c/o Kimberly Harding
180 Elgin Street
Suite 1000
Ottawa
Ontario
K2P 2K3
Canada
+1 613.782.6800
kharding@micronutrient.org

Sponsor type

Other

Website

http://www.micronutrient.org/

Funders

Funder type

Other

Funder name

MICRONUTRIENT INITIATIVE (Canada)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes